Bromodeoxyuridine inhibits cancer cel proliferation in vitro and in vivo

Neoplasia

Volumn 10, Issue 8, 2008, Pages 804-816

  Levkoff, Lindsay H ^a   Marshall II, Gregory P ^a   Ross, Heather H ^a   Caldeira, Maria ^d   Reynolds, Brent A ^d   Cakiroglu, Meryem ^a   Mariani, Christopher L ^b   Streit, Wolfgang J ^a,b,c   Laywell, Eric D ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ARTICLE; CANCER GROWTH; CANCER STEM CELL; CELL CYCLE G1 PHASE; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; DENSITOMETRY; DNA SYNTHESIS; DRUG INHIBITION; FLOW CYTOMETRY; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; RAT; UPREGULATION; WESTERN BLOTTING;

EID: 48249128041     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.08382     Document Type: Article

References (58)

1. Hakala MT (1959). Mode of action of 5-bromodeoxyuridine on mammalian cells in culture. J Biol Chem 234, 3072-3076.
2. Hakala MT (1962). Effect of 5-bromodeoxyuridine incorporation on survival of cultured mammalian cells. Biochim Biophys Acta 61, 815-823.
3. Djordjevic B and Szybalski W (1960). Genetics of human cell lines: III. Incorporation of 5-bromo- and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med 112, 509-531.
4. Littlefield JW and Gould EA (1959). The toxic effect of 5-bromodeoxyuridine on cultured epithelial cells. J Biol Chem 235, 1129-1133.
5. Stellwagen RH and Tomkins GM (1971). Differential effect of 5-bromodeoxyuridine on the concentrations of specific enzymes in hepatoma cells in culture. Proc Natl Acad Sci USA 68, 1147-1150.
6. Dunn DB and Smith JD (1957). Effects of 5-halogenated uracils on the growth of Eschericia coli and their incorporation into deoxyribonucleic acids. Biochem J 67, 494-506.
7. Terzaghi BE, Streisinger G, and Stahl FW (1962). The mechanism of 5-bromouracil mutagenesis in the bacteriophage T4. Proc Natl Acad Sci USA 48, 1519-1524.
8. Cameron HA and McKay RD (2001). Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J Comp Neurol 435, 406-417.
9. Michishita E, Nakabayashi K, Suzuki T, Kaul SC, Ogino H, Fujii M, Mitsui Y, and Ayusawa D (1999). 5-Bromodeoxyuridine induces senescence-like phenomena in mammalian cells regardless of cell type or species. J Biochem 126, 1052-1059.
10. Suzuki T, Minigawa S, Michishita E, Ogino H, Fujii M, Mitsui Y, and Ayusawa D (2001). Induction of senescence-associated genes by 5-bromodeoxyuridine in HeLa cells. Exp Gerontol 36, 465-474.
11. Taupin P (2006). BrdU immunohistochemistry for studying adult neurogenesis: paradigms, pitfalls, limitations, and validation. Brain Res Rev 53, 198-214.
12. Hsu TC and Somers CE (1961). Effect of 5-bromodeoxyuridine on mammalian chromosomes. Proc Natl Acad Sci USA 47, 396-403.
13. Erickson RL and Szybalski W (1963). Molecular radiobiology of human cell lines: V. Comparative radiosensitizing properties of 5-halodeoxycytidines and 5-halode-oxypyrimidines. Radiat Res 20, 252-262.
14. Kinsella TJ, Russo A, Mitchell JB, Rowland J, Jenkins J, Schwade J, Myers CE, Collins JM, Speyer J, Kornblith P, et al. (1984). A phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int J Radiat Oncol Biol Phys 10, 69-76.
15. Phillips TL, Levin WA, Ahn DK, Gutin PH, Wilson CB, Prados MD, Wara WM, and Flam MS (1991). Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California cancer center phase II study. Int J Radiat Oncol Biol Phys 21, 709-714.
16. Robertson JM, McGinn CJ, Walker S, Marx MV, Kessler ML, Ensminger WD, and Lawrence TS (1997). A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Clin Invest 39, 1087-1092.
17. Robertson JM, Ensminger WD, Walker S, and Lawrence TS (1997). A phase I trial of intravenous bromodeoxyuridine and radiation therapy for pancreatic cancer. Clin Invest 37, 331-335.
18. Groves MD, Maor MH, Meyers C, Kyritsis AP, Jaeckle KA, Yung WK, Sawaya RE, Hess K, Bruner JM, Peterson P, et al. (1999). A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme. Clin Invest 45, 127-135.
19. Prados MD, Seiferheld MS, Sandler HM, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, et al. (2004). Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58, 1147-1152.
20. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, Brem H, Olivi A, Dimeco F, and Vescovi AL (2006). Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 444, 761-765.
21. Cochran WG (1977). Sampling Techniques. 3rd Ed. New York, NY: Wiley.
22. Laywell ED, Kearns SM, Zheng T, Chen KA, Deng J, Chen HX, Roper SN, and Steindler DA (2005). Neuron-to-astrocyte transition: phenotypic fluidity and the formation of hybrid asterons in differentiating neurosphere. J Comp Neurol 493, 321-333.
23. Mariani CL, Kouri JG, and Streit WJ (2006). Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes. J Neurooncol 79, 243-253.
24. Reynolds BA and Rietze RL (2005). Neural stem cells and neurospheres - re-evaluating the relationship. Nat Methods 2, 333-336.
25. Marshall GP II, Reynolds BA, and Laywell ED (2007). Using the neurosphere assay to quantify neural stem cells in vivo. Curr Pharm Biotechnol 8, 141-145.
26. Reynolds BA and Weiss S (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255, 1707-1710.
27. Ignatova TN, Kukekov VG, Laywell ED, Suslov ON, Vrionis FD, and Steindler DA (2002). Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39, 193-206.
28. Vescovi AL, Galli R, and Reynolds BA (2006). Brain tumour stem cells. Nat Rev Cancer 6, 425-436.
29. Lin S-C, Chueh S-C, Hsiao C-J, Li T-K, Chen T-H, Liao C-H, Lyu P-C, and Guh J-H (2007). Prazosin displays anticancer activity against human prostate cancers: targeting DNA and cell cycle. Neoplasia 9, 830-839.
30. Michishita E, Kurahashi T, Suzuki T, Fukuda M, Fujii M, Hirano H, and Ayusawa D (2002). Changes in nuclear matrix proteins during the senescence-like phenomenon induced by 5-chlorodeoxyuridine in HeLa cells. Exp Gerontol 37, 885-890.
31. Hammill AK, Uhr JW, and Scheuermann RH (1999). Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res 251, 16-21.
32. Holder MJ, Barnes NM, Gregory CD, and Gordon J (2006). Lymphoma cells protected from apoptosis by dysregulated Bcl-2 continue to bind annexin V in response to B-cell receptor engagement: a cautionary tale. Leuk Res 30, 77-80.
33. Weinberg RA (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
34. Minagawa S, Nakabayashi K, Fujii M, Scherer SW, and Ayusawa D (2005). Early BrdU-responsive genes constitute a novel class of senescence-associated genes in human cells. Exp Cell Res 304, 552-558.
35. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O, et al. (1995). A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 92, 9363-9367.
36. de Lange T (2006). Mammalian telomeres. Telomeres. Woodbury, NY: Cold Spring Harbor Press, 341-387.
37. Dunham MA, Neumann AA, Fasching CL, and Reddel RR (2000). Telomere maintenance by recombination in human cells. Nat Genet 26, 447-450.
38. Mandal S, Guptan P, Owusu-Ansah E, and Banerjee U (2005). Mitochondrial regulation of cell cycle progression during development as revealed by the tenured mutation in Drosophila. Dev Cell 9, 843-854.
39. Davis AF and Clayton DA (1996). In situ localization of mitochondrial DNA replication in intact mammalian cells. J Cell Biol 135, 883-893.
40. Ashman CR and Davidson RL (1981). Bromodeoxyuridine mutagenesis in mammalian cells is related to deoxyribonucleotide pool imbalance. Mol Cell Biol 1, 254-260.
41. Kaufman ER and Davidson RL (1978). Bromodeoxyuridine mutagenesis in mammalian cells: mutagenesis is independent of the amount of bromouracil in DNA. Proc Natl Acad Sci USA 75, 4982-4986.
42. Meuth M and Green H (1974). Induction of a deoxycytidineless state in cultured mammalian cells by bromodeoxyuridine. Cell 2, 109-112.
43. Moore EC and Hurlbert RB (1966). Regulation of mammalian deoxyribonucleotide biosynthesis by nucleotides as activators and inhibitors. J Biol Chem 241, 4802-4809.
44. Hopkins RL and Goodman MF(1980). Deoxyribonucleotide pools, base pairing, and sequence configuration affecting bromodeoxyuridine-and 2-aminopuridine- induced mutagenesis. Proc Natl Acad Sci USA 77, 1801-1805.
45. Davidson RL and Kaufman ER (1978). Bromodeoxyuridine mutagenesis in mammalian cells is stimulated by thymidine and suppressed by deoxycytidine. Nature 276, 722-733.
46. Ko L, Koestner A, and Wechsler W (1980). Morphological characterization of nitrosourea-induced glioma cell lines and clones. Acta Neuropathol 51, 23-31.
47. Aas AT, Brun A, Blennow C, Stromblad S, and Salford LG (1995). The RG2 rat glioma model. J Neurooncol 23, 175-183.
48. Barth RF (1998). Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol 36, 91-102.
49. Campisi J (2005). Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513-522.
50. Liu D and Hornsby PJ (2007). Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stress-induced premature senescence does not increase effect. Neoplasia 9, 418-426.
51. Severino J, Allen RG, Balin S, and Cristofalo VJ (2000). Is β-galactosidase staining a marker of senescence in vitro and in vivo? Exp Cell Res 257, 162-171.
52. Thomas DM, Yang H-S, Alexander K, and Hinds PW (2003). Role of the retinoblastoma protein in differentiation and senescence. Cancer Biol Ther 2, 124-130.
53. Fujii M, Ito H, Hasegawa T, Suzuki T, Adachi N, and Ayusawa D (2002). 5-Bromo-2′-deoxyuridine efficiently suppresses division potential of the yeast Saccharomyces cerevisiae. Biosci Biotechnol Biochem 66, 906-909.
54. Akman F, Cooper RA, Sen M, Tanriver Y, and Kentli S (2002). Validation of the Medical Research Council and a newly developed prognostic index in patients with malignant glioma: how useful are prognostic indices in routine clinical practice? J Neurooncol 59, 39-47.
55. Basso U, Ermani M, Vastola F, and Brandes AA (2002). Non-cytotoxic therapies for malignant gliomas. J Neurooncol 58, 57-69.
56. Nieder C, Grosu AL, and Molls M (2000). A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26, 397-409.
57. Mariani CL, Rajon D, Bova FJ, and Streit WJ (2007). Nonspecific immunotherapy with intratumoral lipopolysaccharide and zymosan A but not GMCSF leads to an effective anti-tumor response in subcutaneous RG-2 gliomas. J Neurooncol 85, 231-240.
58. Phillips TL, Bodell WJ, Uhl B, Ross GY, Rasmussen J, and Mitchell JB (1989). Correlation of exposure time, concentration, and incorporation of IdURD in V-79 cells with radiation exposure. Int J Radiat Oncol Biol Phys 16, 1251-1255.